Mark I. Kemp

626 total citations
15 papers, 396 citations indexed

About

Mark I. Kemp is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Organic Chemistry. According to data from OpenAlex, Mark I. Kemp has authored 15 papers receiving a total of 396 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 5 papers in Cellular and Molecular Neuroscience and 4 papers in Organic Chemistry. Recurrent topics in Mark I. Kemp's work include Ion channel regulation and function (5 papers), Neuroscience and Neuropharmacology Research (4 papers) and Protein Degradation and Inhibitors (3 papers). Mark I. Kemp is often cited by papers focused on Ion channel regulation and function (5 papers), Neuroscience and Neuropharmacology Research (4 papers) and Protein Degradation and Inhibitors (3 papers). Mark I. Kemp collaborates with scholars based in United Kingdom, United States and Romania. Mark I. Kemp's co-authors include Stephen P. Jackson, Niall M.B. Martin, Xavier Jacq, Kevin Beaumont, Rhys D.O. Jones, Steven D. Buckingham, C.A.R. Boyd, Valérie Raymond, David B. Sattelle and Peter J. Bungay and has published in prestigious journals such as Nature Communications, Cancer Research and British Journal of Pharmacology.

In The Last Decade

Mark I. Kemp

14 papers receiving 387 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark I. Kemp United Kingdom 10 288 81 70 66 51 15 396
Robert J. Cassell United States 10 412 1.4× 163 2.0× 65 0.9× 78 1.2× 36 0.7× 15 532
Jinquan Cui China 15 338 1.2× 135 1.7× 39 0.6× 77 1.2× 39 0.8× 36 531
Vincent Zwick Switzerland 8 340 1.2× 50 0.6× 94 1.3× 82 1.2× 30 0.6× 13 421
Jean‐Claude Galleyrand France 11 196 0.7× 134 1.7× 44 0.6× 27 0.4× 58 1.1× 18 398
Per Olaf Huusfeldt Denmark 9 423 1.5× 157 1.9× 79 1.1× 128 1.9× 39 0.8× 11 793
Adam Flegg United Kingdom 4 191 0.7× 56 0.7× 70 1.0× 103 1.6× 85 1.7× 4 498
Yasunobu Ishihara Japan 12 265 0.9× 103 1.3× 37 0.5× 55 0.8× 52 1.0× 30 545
Christina Rye Underwood Denmark 11 497 1.7× 222 2.7× 48 0.7× 37 0.6× 36 0.7× 16 653
Jean‐François Patoiseau France 10 233 0.8× 53 0.7× 52 0.7× 44 0.7× 44 0.9× 23 480
Zhijian Hu United States 9 147 0.5× 38 0.5× 35 0.5× 61 0.9× 94 1.8× 32 340

Countries citing papers authored by Mark I. Kemp

Since Specialization
Citations

This map shows the geographic impact of Mark I. Kemp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark I. Kemp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark I. Kemp more than expected).

Fields of papers citing papers by Mark I. Kemp

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark I. Kemp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark I. Kemp. The network helps show where Mark I. Kemp may publish in the future.

Co-authorship network of co-authors of Mark I. Kemp

This figure shows the co-authorship network connecting the top 25 collaborators of Mark I. Kemp. A scholar is included among the top collaborators of Mark I. Kemp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark I. Kemp. Mark I. Kemp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Sun, Yu, Andrew C. Pearce, Simona Eleuteri, et al.. (2023). Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson’s disease mouse model. Nature Communications. 14(1). 7295–7295. 43 indexed citations
2.
Brown, Alan D., Sharan K. Bagal, David C. Blakemore, et al.. (2018). The discovery and optimization of benzimidazoles as selective NaV1.8 blockers for the treatment of pain. Bioorganic & Medicinal Chemistry. 27(1). 230–239. 22 indexed citations
3.
Kemp, Mark I.. (2016). Recent Advances in the Discovery of Deubiquitinating Enzyme Inhibitors. Progress in medicinal chemistry. 55. 149–192. 57 indexed citations
4.
Bagal, Sharan K., Mark I. Kemp, Peter J. Bungay, et al.. (2016). Discovery and optimisation of potent and highly subtype selective Nav1.8 inhibitors with reduced cardiovascular liabilities. MedChemComm. 7(10). 1925–1931. 5 indexed citations
5.
Bagal, Sharan K., Peter J. Bungay, Karl R. Gibson, et al.. (2015). Discovery and Optimization of Selective Na v 1.8 Modulator Series That Demonstrate Efficacy in Preclinical Models of Pain. ACS Medicinal Chemistry Letters. 6(6). 650–654. 36 indexed citations
6.
Jacq, Xavier, Niall M.B. Martin, Lisa M. Smith, et al.. (2015). Abstract 1728: Discovery of highly selective DUB inhibitors with in vivo pre-clinical anti-tumor activity. Cancer Research. 75(15_Supplement). 1728–1728. 1 indexed citations
7.
Jacq, Xavier, Mark I. Kemp, Niall M.B. Martin, & Stephen P. Jackson. (2013). Deubiquitylating Enzymes and DNA Damage Response Pathways. Cell Biochemistry and Biophysics. 67(1). 25–43. 73 indexed citations
8.
Kemp, Mark I.. (2010). Structural Trends among Second-Generation Voltage-Gated Sodium Channel Blockers. Progress in medicinal chemistry. 49. 81–111. 14 indexed citations
9.
10.
11.
Good, G. M., Mark I. Kemp, & William J. Kerr. (2000). Facile chromium carbene mediated synthesis of functionalised 5- to 7-ring lactones. Tetrahedron Letters. 41(48). 9323–9326. 4 indexed citations
12.
Small, Ben G., Mark I. Kemp, Ken H. Hoo, et al.. (1998). LY339434, a GluR5 kainate receptor agonist. Neuropharmacology. 37(10-11). 1261–1267. 34 indexed citations
13.
Kemp, Mark I.. (1998). A Zirconium-Mediated Synthesis of (±)-Tecomanine. Synthesis. 1998(S1). 552–556. 8 indexed citations
14.
Kemp, Mark I.. (1998). Zirconocene-Mediated Synthesis of 3,4-Disubstituted Piperidines and Reduced Isoquinolines. Synthesis. 1998(S1). 557–568. 9 indexed citations
15.
Kemp, Mark I., Richard J. Whitby, & Steven J. Coote. (1994). Zirconocene-Mediated Synthesis of 3,4-Disubstituted Piperidines and Reduced Isoquinolines. Synlett. 1994(6). 451–453. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert J. Cassell Breakdown of academic impact, for papers by Jinquan Cui Breakdown of academic impact, for papers by Vincent Zwick Breakdown of academic impact, for papers by Jean‐Claude Galleyrand Breakdown of academic impact, for papers by Per Olaf Huusfeldt Breakdown of academic impact, for papers by Adam Flegg Breakdown of academic impact, for papers by Yasunobu Ishihara Breakdown of academic impact, for papers by Christina Rye Underwood Breakdown of academic impact, for papers by Jean‐François Patoiseau Breakdown of academic impact, for papers by Zhijian Hu
Rankless by CCL
2026